Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
RESEARCH TOOLSreports
Total Valuation
Medicenna Therapeutics Corp has a market cap or net worth of C$52.59M. The enterprise value is $49.85M.
Market CapC$52.59M
Enterprise Value$49.85M
Share Statistics
Medicenna Therapeutics Corp has 68,726,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,726,980
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Medicenna Therapeutics Corp’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -81.50%.
Return on Equity (ROE)-0.62
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-81.50%
Return on Capital Employed (ROCE)-0.90
Revenue Per Employee0.00
Profits Per Employee-737.81K
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Medicenna Therapeutics Corp is ―. Medicenna Therapeutics Corp’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value3.93
Price to FCF―
Price to Operating Cash Flow-4.94
PEG Ratio―
Income Statement
In the last 12 months, Medicenna Therapeutics Corp had revenue of 0.00 and earned -11.80M in profits. Earnings per share was -0.15.
Revenue0.00
Gross Profit-55.00K
Operating Income-21.63M
Pretax Income-13.03M
Net Income-11.80M
EBITDA-12.97M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was -17.71M and capital expenditures -2.00K, giving a free cash flow of -17.71M billion.
Operating Cash Flow-17.71M
Free Cash Flow-17.71M
Free Cash Flow per Share-0.26
Dividends & Yields
Medicenna Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-48.76%
50-Day Moving Average0.70
200-Day Moving Average0.82
Relative Strength Index (RSI)52.24
Average Volume (3m)58.17K
Important Dates
Medicenna Therapeutics Corp upcoming earnings date is Nov 14, 2025, Before Open (Confirmed).
Last Earnings DateAug 1, 2025
Next Earnings DateNov 14, 2025
Ex-Dividend Date―
Financial Position
Medicenna Therapeutics Corp as a current ratio of 6.35, with Debt / Equity ratio of 1.11%
Current Ratio6.35
Quick Ratio6.35
Debt to Market Cap<0.01
Net Debt to EBITDA1.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Medicenna Therapeutics Corp has paid -1.23M in taxes.
Income Tax-1.23M
Effective Tax Rate0.09
Enterprise Valuation
Medicenna Therapeutics Corp EV to EBITDA ratio is -3.89, with an EV/FCF ratio of -3.05.
EV to Sales0.00
EV to EBITDA-3.89
EV to Free Cash Flow-3.05
EV to Operating Cash Flow-3.06
Balance Sheet
Medicenna Therapeutics Corp has C$20.46M in cash and marketable securities with C$162.00K in debt, giving a net cash position of -C$20.30M billion.
Cash & Marketable SecuritiesC$20.46M
Total DebtC$162.00K
Net Cash-C$20.30M
Net Cash Per Share-C$0.30
Tangible Book Value Per ShareC$0.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Medicenna Therapeutics Corp is C$2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$2.50
Price Target Upside228.63% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―